[Click eStock] "STCube, Potential of Immune Checkpoint Inhibitor Pipeline"

[Asia Economy Reporter Jang Hyowon] IBK Investment & Securities analyzed on the 9th that STCube shows potential in its immune checkpoint inhibitor pipeline. No investment opinion or target price was provided.

Moon Kyungjun, a researcher at IBK Investment & Securities, stated in a report on the same day, “STCube possesses an immune checkpoint inhibitor mechanism anticancer drug pipeline,” and explained, “The best-in-class pipeline is being developed as a drug that suppresses tumor cell growth through a complex mechanism compared to existing PD-L1 class drugs.”

Researcher Moon said, “The overall immune checkpoint inhibitor market is showing an annual growth rate of 19%, and the current market size is estimated to exceed approximately 30 trillion KRW,” adding, “Despite the safety and high efficacy of immune checkpoint inhibitors as anticancer drugs, the response rate of patients treated with monotherapy is less than 20%, so clinical trials combining other treatment methods are rapidly increasing.”

He analyzed, “STT-003, an antibody under development, and STT-011, a small molecule compound under development, are STCube’s first-in-class pipelines targeting an important immune regulatory substance that suppresses immune anticancer functions similarly to PD-1 and PD-L1,” and added, “STT-003 is expressed mutually exclusively with PD-L1 in tumor cells, which is likely to attract market interest.”

Furthermore, he added, “Combination therapy with the PD-L1 class is also expected to be possible, and STCube plans to conduct clinical trials targeting solid tumors as indications in the future.”